We specialise in orphan, rare and oncology diseases. Rare diseases affect 1 in 10 people, meaning more than 350 million people worldwide*. These people are often overlooked as the exceptionally low incidence of these diseases creates significant challenges in the design and execution of clinical trials for new therapeutics.
We understand those challenges and are proud that our dedicated global team of world-class experts and specialists have probably more orphan product and cell therapy experience than any other clinical research organisation.
Our team passionately believes that those affected by orphan, rare and oncology diseases should not feel marginalised in society by their conditions. That’s why we’re dedicated to bringing therapies to market that will allow those affected to live as normal a life as possible.